Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate

Br J Cancer. 2022 Nov;127(8):1383-1384. doi: 10.1038/s41416-022-01930-3. Epub 2022 Sep 5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Programmed Cell Death 1 Receptor

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor